Explain this page
Arphra AIPlain-English read on Boston Scientific Corporation’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09% | -2.23% | -15.69% | -35.50% | -51.67% | -50.04% | -53.80% | -7.32% | +15.20% | +108.93% | +1012.64% |
Aftermarket
LiveLast trade
$47.63
966 sh
Bid
$47.59
1,800 sh
Ask
$47.67
500 sh
Spread
$0.080
Sector & industry today
LiveSectors
- Healthcare+1.73%
- Financial Services+1.62%
- Industrials+1.19%
- Real Estate+0.90%
- Energy+0.89%
- Consumer Defensive+0.65%
- Consumer Cyclical+0.59%
- Basic Materials+0.06%
- Utilities-0.53%
- Technology-1.85%
- Communication Services-2.33%
Top industries (issuer's industry highlighted)
- Medical - Devices-0.09%
- Investment - Banking & Investment Services-4.27%
- Broadcasting-4.14%
- Rental & Leasing Services+4.02%
- Software - Infrastructure-3.76%
- Software - Application-3.71%
- Electronic Gaming & Multimedia-3.27%
- Internet Content & Information-3.02%
- Auto - Recreational Vehicles+2.96%
- Computer Hardware-2.88%
- Financial - Mortgages-2.86%
- Solar-2.84%
Fair value
Football field →Weighted blend
$369.14
+674.93% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
5bull8bear
±5% threshold
Analyst PT consensus: $91.33 (+91.73%)
Total assets
$43.67B
Total debt
$12.42B
Cash & equiv
$2.05B
Operating CF
$4.53B
Free cash flow
$3.66B
Buybacks
$0
Analyst view
DB · price_targets + analyst_gradesConsensus target
$91.33
+91.73% upside
Low
$60.00
Median
$90.00
High
$120.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- BSX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026businesswire.com·May 04, 2026
- BSX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026businesswire.com·May 04, 2026
- BSX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSXnewsfilecorp.com·May 04, 2026
- BSX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSXnewsfilecorp.com·May 04, 2026
- Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 resultsprnewswire.com·May 04, 2026
- Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 resultsprnewswire.com·May 04, 2026
- BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSXglobenewswire.com·May 03, 2026
- BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSXglobenewswire.com·May 03, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $5.2B | $1.34B | $0.90 |
| Q4 Dec 2025 | $5.29B | $668M | $0.45 |
| Q3 Sep 2025 | $5.07B | $755M | $0.50 |
| Q2 Jun 2025 | $5.06B | $793M | $0.53 |
| Q1 Mar 2025 | $4.66B | $674M | $0.45 |
| Q4 Dec 2024 | $4.56B | $566M | $0.38 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Mahoney Michael F director, officer: Chairman, President & CEO | Sell | 1,200 | $112.87K | Feb 02, 2026 |
Mahoney Michael F director, officer: Chairman, President & CEO | Sell | 159,701 | $14.93M | Feb 02, 2026 |
Butcher Arthur C officer: EVP& Grp Pres, MedSurg & APAC | Sell | 17,313 | $1.76M | Dec 01, 2025 |
Zane Ellen M director | Sell | 12,891 | $1.27M | Nov 06, 2025 |
Fitzgerald Joseph Michael officer: EVP & Group Pres, Cardiology | Sell | 3,600 | $362.69K | Nov 03, 2025 |
Fitzgerald Joseph Michael officer: EVP & Group Pres, Cardiology | Sell | 16,928 | $1.69M | Nov 03, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $20.07B | $3.97B | $2.89B | $1.94 | +14.38% |
| FY 2024 | $16.75B | $2.64B | $1.85B | $1.25 | +11.07% |
| FY 2023 | $14.24B | $2.18B | $1.59B | $1.07 | +11.19% |
| FY 2022 | $12.68B | $1.82B | $698M | $0.45 | +5.50% |
| FY 2021 | $11.89B | $1.92B | $1.04B | $0.69 | +8.75% |